Board of Directors
Charles O’Hanlon
Thomas Petzinger, Jr.
Paul Kornblith, M.D.
Eric T. Ahrens, Ph.D.
Daniel P. Gallagher, Jr.
Ronald B. Herberman, M.D.
Kevin S. McClatchy
L. Gerald Tarantino
D. Lansing Taylor, Ph.D.
Charles F. O’Hanlon, President and CEO. Mr. O’Hanlon was previously a Managing Director of Cornerstone Capital Advisors, of Pittsburgh, PA, where he provided financial and operating advice, interim management, and corporate finance services to privately held businesses. While at Cornerstone, he was involved in the founding of numerous new ventures, spin offs, and re-starts of distressed companies. Prior to joining Cornerstone in 2001, Mr. O’Hanlon spent 30 years in commercial banking in various executive capacities. Mr. O’Hanlon serves on the boards of several private companies. He studied management and operations research at Georgia Tech, and received an MBA from Robert Morris College in 1980.
Thomas Petzinger, Jr., Secretary and Treasurer. Mr. Petzinger is also the CEO of LaunchCyte LLC, and has formed five other life sciences ventures. He spent 22 years at The Wall Street Journal, where he served as Washington economics editor, deputy Washington bureau chief, millennium editor, and weekly columnist. He received his B.S. in Journalism from Northwestern University, where he was a Richter International Scholar.
Paul Kornblith, M.D., Chairman of the Board of Directors. Dr. Kornblith is a renowned neurosurgeon, academic, and inventor, and founded Precision Therapeutics Inc. of Pittsburgh. He trained at Temple University, Jefferson Medical College, the University of Pennsylvania, and Massachusetts General Hospital.
Eric T. Ahrens, Ph.D., Founder and Chief Scientific Officer. Dr. Ahrens is also an associate professor in the Department of Biological Sciences at Carnegie Mellon University. Dr. Ahrens earned his B.S., M.S., and Ph.D. degrees in physics from the University of California at Los Angeles, and has authored more than 40 scholarly publications in biology and physics, many relating to cellular/molecular MRI.
Daniel P. Gallagher, Jr., is a partner with the Pittsburgh office of Reed Smith. Mr. Gallagher’s legal practice is currently devoted to a wide variety of financial and international business, investment and joint venture transactions. Mr. Gallagher received his J.D. from the University of Chicago and his B.A. with Honors from Yale University.
Ronald B. Herberman, M.D., is Director of the University of Pittsburgh Cancer Institute (UPCI) and of the UPMC Cancer centers. He is an internationally recognized tumor immunologist who has made major discoveries in his field, most notably the initial descriptions of natural killer [NK] cells, and he has fostered the application of this information to novel approaches to cancer therapy. His pioneering investigations of NK cells demonstrated their important role in resistance to the metastatic spread of cancer.
Kevin S. McClatchy is private investor and a former media and entertainment company executive. Mr. McClatchy is currently a director of McClatchy Newspapers, Inc. From 1996 to 2007 he was the managing general partner and chief executive officer of the Pittsburgh Pirates Major League Baseball team. Mr. McClatchy earned his B.A. in Political Science at University of California at Santa Barbara.
L. Gerald Tarantino, J.D., is a retired executive and private investor. Mr. Tarantino began his career as a Wall Street securities lawyer. For the past twenty-five years he has been the owner/manager of a range of small and medium sized businesses, both private and public, in diverse areas and industries, including sophisticated software, information technology, biotechnology, and the Internet. He holds a B.A. and an LLB from the University of Pennsylvania.
D. Lansing Taylor, Ph.D., is the CEO of Cellumen, Inc., a cell-based drug discovery company, and founded Cellomics Inc., where he was Chairman and CEO from 1996-2004. Dr. Taylor was a Professor of Biological Sciences, Vice Dean of Molecular Sciences and Director of the National Science Foundation, Science and Technology Center (STC) at Carnegie Mellon between 1982 and 1996. He began his academic and research career at Harvard University.